Sprint Bioscience
Cancer

Developing breakthrough oncology drug candidates

Sprint Bioscience

Our research & development

Read more Read more
Press releases

Don't miss any news, subscribe on our press releases.

Subscribe to our newsletter Subscribe to our newsletter
Our innovation

We are driven by make a difference for those affected by cancer

Sprint Bioscience is a pharmaceutical company focused on developing innovative drug candidates that can contribute to new treatments for cancer. The great need for new treatments for difficult-to-treat cancer brings great commercial potential.

Using a fragment-based drug development approach, we develop drug programs in a time- and resource-efficient manner that are out-licensed to global pharmaceutical companies during the preclinical phase.

Press releases

Show all Show all

Read our articles

Show all Show all

Sprint Bioscience signs deal valued up to $400 million

Sprint Bioscience has sold one of its cancer programs, TREX1, to Gilead Sciences, Inc. The deal includes an upfront payment of USD 14 million and potential milestone payments related to clinical, regulatory and commercial progress, which could total up to USD 400 million. Read more about the deal in the press release from November 24 or in one of the news articles...
Read more
1 Dec 2025

New strategic partnership and research collaboration

Sprint Bioscience has entered into a research collaboration with the Experimental Drug Development Centre (EDDC) in Singapore to expand Sprint Bioscience's MASH (Metabolic dysfunction-associated steatohepatitis) program into inflammatory diseases. Under the collaboration, compounds developed by Sprint Bioscience in the program will be evaluated by EDDC - Singapore's national platform for drug discovery and development and part of the...
Read more
19 Jun 2025

Strategic partnership strengthens Sprint Biosciences' capabilities

In our work to develop small-molecule preclinical drug candidates that can contribute to new cancer therapies, speed and precision are crucial. By collaborating with SciLifeLab's Drug Discovery and Development (DDD) Platform, we gain access to advanced protein quality analysis - a key component of our fragment-based drug development. This infrastructure enables us to...
Read more
4 Jun 2025

Sprint Biosciences upcoming activities

On April 8, the subscription period for Sprint Bioscience's rights issue began. The subscription rights are traded on First North Premier Growth Market until April 17, 2025, and the subscription period continues until April 24, 2025. More information can be found here. Read BioStock's interview (in Swedish) with CEO Johan Emilsson about the ongoing rights issue. See the latest Company Presentation, in the studio at [...]
Read more
10 Apr 2025

Happening in the future

Show all Show all

Front Page